CASI
CASI
NASDAQ · Biotechnology

Casi Pharmaceuticals Inc

$0.15
+0.01 (+3.57%)
Financial Highlights (FY 2026)
Revenue
38.23M
Net Income
-52,587,129
Gross Margin
55.9%
Profit Margin
-137.6%
Rev Growth
-1.8%
D/E Ratio
9.93
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 55.9% 55.9% 60.0% 60.0%
Operating Margin -138.8% -125.0% 5.5% 5.7%
Profit Margin -137.6% -130.7% 4.6% 6.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 38.23M 38.94M 9.51M 9.21M
Gross Profit 21.36M 21.76M 5.70M 5.53M
Operating Income -53,072,900 -48,660,971 525.4K 529.8K
Net Income -52,587,129 -48,215,582 434.3K 561.3K
Gross Margin 55.9% 55.9% 60.0% 60.0%
Operating Margin -138.8% -125.0% 5.5% 5.7%
Profit Margin -137.6% -130.7% 4.6% 6.1%
Rev Growth -1.8% -1.8% +3.9% +7.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.35M 1.35M 2.23M 2.01M
Total Equity 136.3K 136.3K 5.80M 5.32M
D/E Ratio 9.93 9.93 0.38 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -52,539,868 -50,848,486 716.5K 618.7K
Free Cash Flow 350.1K 392.2K